Goldman Sachs
ATXI

Goldman Sachs’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Goldman Sachs’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-21
Closed -$58K – 6571
2021
Q2 		$58K Buy
21
+6
+40% +$29.6K ﹤0.01% 6054
2021
Q1 		$105K Buy
+15
New +$103K ﹤0.01% 5834
2020
Q2 		– Sell
-14
Closed -$138K – 5529
2020
Q1 		$138K Buy
+14
New +$140K ﹤0.01% 4856
2017
Q4 		– Sell
-14
Closed -$89K – 6712
2017
Q3 		$89K Sell
14
-10
-42% -$73.4K ﹤0.01% 6100
2017
Q2 		$219K Buy
+24
New +$216K ﹤0.01% 5739

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's ATXI Position: Q3 2021 in Review

Goldman Sachs sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q3 2021, closing a stake of 21 shares — an estimated $58K sold.

Goldman Sachs first reported a position in ATXI in Q2 2017 and held it in 5 quarters. The position peaked at $219K in Q2 2017. 17 funds tracked by Wall St. Rank hold ATXI as of Q3 2021.

  • Goldman Sachs reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 21 Avenue Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $58K.
  • Goldman Sachs first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2017 and held it in 5 quarters.
  • Goldman Sachs's Avenue Therapeutics, Inc. Common Stock position peaked at $219K in Q2 2017.
  • 17 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.